Login Register Cart 0
Research Article

Therapeutic Potential of Melatonin in the Regulation of MiR-148a-3p and Angiogenic Factors in Breast Cancer

Author(s): Jéssica Zani Lacerda, Lívia Carvalho Ferreira, Beatriz Camargo Lopes, Andrés Felipe Aristizábal-Pachón, Marcio Chaim Bajgelman, Thaiz Ferraz Borin and Debora Aparecida Pires de Campos Zuccari*

Volume 8, Issue 3, 2019

Page: [237 - 247] Pages: 11

DOI: 10.2174/2211536608666190219095426

Price: $65

Abstract

Background: The high mortality rate of breast cancer is related to the occurrence of metastasis, a process that is promoted by tumor angiogenesis. MicroRNAs are small molecules of noncoding mRNA that play a key role in gene regulation and are directly involved in the progression and angiogenesis of various tumor types, including breast cancer. Several miRNAs have been described as promoters or suppressors angiogenesis and may be associated with tumor growth and metastasis. Melatonin is an oncostatic agent with a capacity of modifying the expression of innumerable genes and miRNAs related to cancer.

Objective: The aim of this study was to evaluate the role of melatonin and the tumor suppressor miR- 148a-3p on angiogenesis of breast cancer.

Method: MDA-MB-231 cells were treated with melatonin and modified with the overexpression of miR-148a-3p. The relative quantification in real-time of miR-148a-3p, IGF-IR and VEGF was performed by real-time PCR. The protein expression of these targets was performed by immunocytochemistry and immunohistochemistry. Survival, migration and invasion rates of tumor cells were evaluated. Finally, the xenograft model of breast cancer was performed to confirm the role of melatonin in the tumor.

Results: The melatonin was able to increase the gene level of miR-148a-3p and decreased the gene and protein expression of IGF-1R and VEGF, both in vitro and in vivo. In addition, it also had an inhibitory effect on the survival, migration and invasion of breast tumor cells.

Conclusion: Our results confirm the role of melatonin in the regulation of miR-148a-3p and decrease of angiogenic factors.

Keywords: Angiogenic proteins, miRNA, pineal gland, triple negative breast cancer, tumor cells, xenograft model.

« Previous Next »
Graphical Abstract

[1]
INCA - Instituto Nacional de Câncer INCA . 2018.
[2]
Walker RA, Jones JL, Chappell S, Walsh T, Shaw JA. Molecular pathology of breast cancer and its application to clinical management. Cancer Metastasis Ver 1997; 16(1-2): 5-27.
[3]
Redig AJ, McAllister SS. Breast cancer as a systemic disease: a view of metastasis. J Intern Med 2013; 274(2): 113-26.
[4]
Hicks DG, Kulkarni S. Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing. Arch Pathol Lab Med 2008; 132(6): 1008-15.
[5]
Park SY, Jang WJ, Yi EY, et al. Melatonin suppresses tumor angiogenesis by inhibiting HIF-1alpha stabilization under hypoxia. J Pineal Res 2010; 48(2): 178-84.
[6]
Wang Z, Dabrosin C, Yin X, et al. Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol 2015; 35(Suppl.): S224-43.
[7]
Danza K, De Summa S, Pinto R, et al. MiR-578 and miR-573 as potential players in BRCA-related breast cancer angiogenesis. Oncotarget 2015; 6(1): 471-83.
[8]
Calin GA, Ferracin M, Cimmino A, et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353(17): 1793-801.
[9]
Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449(7163): 682-8.
[10]
Bertoli G, Cava C, Castiglioni I. MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer. Theranostics 2015; 5(10): 1122-43.
[11]
Wang S, Olson EN. AngiomiRs-key regulators of angiogenesis. Curr Opin Genet Dev 2009; 19(3): 205-11.
[12]
Di Bella G, Mascia F, Ricchi A, Colori B. Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report. Neuroendocrinol Lett 2013; 34(7): 660-8.
[13]
Sousa-Neto JA, Scaldaferri PM. Melatonina e câncer -revisão da literatura. Rev Bras Cancerol 2005; 51(1): 49-58.
[14]
Alvarez-García V, González A, Alonso-González C, Martínez-Campa C, Cos S. Regulation of vascular endothelial growth factor by melatonin in human breast cancer cells. J Pineal Res 2013; 54(4): 373-80.
[15]
Jardim-Perassi BV, Arbab AS, Ferreira LC, et al. Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer. PLoS One 2014; 9(1): e85311.
[16]
Cucina A, Proietti S, D’Anselmi F, et al. Evidence for a biphasic apoptotic pathway induced by melatonin in MCF-7 breast cancer cells. J Pineal Res 2009; 46(2): 172-80.
[17]
Girgert R, Hanf V, Emons G, Gründker C. Membrane-bound melatonin receptor MT1 down-regulates estrogen responsive genes in breast cancer cells. J Pineal Res 2009; 47(1): 23-31.
[18]
Martínez-Campa CM, Alonso-González C, Mediavilla MD, Cos S, González A, Sanchez-Barcelo EJ. Melatonin down-regulates hTERT expression induced by either natural estrogens (17beta-estradiol) or metalloestrogens (cadmium) in MCF-7 human breast cancer cells. Cancer Lett 2008; 268(2): 272-7.
[19]
Lee SE, Kim SJ, Youn J-P, Hwang SY, Park C-S, Park YS. MicroRNA and gene expression analysis of melatonin-exposed human breast cancer cell lines indicating involvement of the anticancer effect. J Pineal Res 2011; 51(3): 345-52.
[20]
Chen Y, Song Y-X, Wang Z-N. The microRNA-148/152 family: multi-faceted players. Mol Cancer 2013; 12: 43.
[21]
Friedrich M, Pracht K, Mashreghi M-F, Jäck H-M, Radbruch A, Seliger B. The role of the miR-148/-152 family in physiology and disease. Eur J Immunol 2017; 47(12): 2026-38.
[22]
Xu Q, Jiang Y, Yin Y, et al. A regulatory circuit of miR- 148 a / 152 and DNMT 1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS 1. J Mol Cell Biol 2013; 5: 3-13.
[23]
Hiroki E, Akahira J, Suzuki F, et al. Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci 2010; 101(1): 241-9.
[24]
Tsuruta T, Kozaki K, Uesugi A, et al. miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res 2011; 71(20): 6450-62.
[25]
Braconi C, Huang N, Patel T. MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology 2010; 51(3): 881-90.
[26]
Stewart SA, Dykxhoorn DM, Palliser D, et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 2003; 9(4): 493-501.
[27]
Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009; 55(4): 611-22.
[28]
Xu Q, Jiang Y, Yin Y, et al. A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1. J Mol Cell Biol 2013; 5(1): 3-13.
[29]
Boudreau N, Myers C. Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment. Breast Cancer Res 2003; 5(3): 140-6.
[30]
Tominaga N, Katsuda T, Ochiya T. Micromanaging of tumor metastasis by extracellular vesicles. Semin Cell Dev Biol 2015; 40: 52-9.
[31]
Borin TF, Arbab AS, Gelaleti GB, et al. Melatonin decreases breast cancer metastasis by modulating Rho-associated kinase protein-1 expression. J Pineal Res 2016; 60(1): 3-15.
[32]
Gelaleti GB, Borin TF, Maschio-Signorini LB, et al. Efficacy of melatonin, IL-25 and siIL-17B in tumorigenesis-associated properties of breast cancer cell lines. Life Sci 2017; 183: 98-109.
[33]
Lopes JR, Kavagutti M da S, de Medeiros FAF. de Campos Zuccari DAP. Evaluation of melatonin effect on human breast cancer stem cells using a threedimensional growth method of mammospheres. Anticancer Agents Med Chem 2017; 17(7): 961-5.
[34]
Jardim-Perassi BV, Lourenço MR, Doho GM, et al. Melatonin regulates angiogenic factors under hypoxia in breast cancer cell lines. Anticancer Agents Med Chem 2016; 16(3): 347-8.
[35]
Maschio-Signorini LB, Gelaleti GB, Moschetta MG, et al. Melatonin regulates angiogenic and inflammatory proteins in MDA-MB-231 cell line and in co-culture with cancer-associated fibroblasts. Anticancer Agents Med Chem 2016; 16(11): 1474-84.
[36]
Cos S, Blask DE, Lemus-Wilson A, Hill AB. Effects of melatonin on the cell cycle kinetics and “estrogen-rescue” of MCF-7 human breast cancer cells in culture. J Pineal Res 1991; 10(1): 36-42.
[37]
Kilic E, Kilic Ü, Reiter RJ, Bassetti CL, Hermann DM. Prophylactic use of melatonin protects against focal cerebral ischemia in mice: role of endothelin converting enzyme-1. J Pineal Res 2004; 37(4): 247-51.
[38]
Lissoni P, Rovelli F, Malugani F, Bucovec R, Conti A, Maestroni GJ. Anti-angiogenic activity of melatonin in advanced cancer patients. Neuroendocrinol Lett 2001; 22(1): 45-7.
[39]
Alicia González-González, Alicia González, Carolina Alonso- González, Javier Menéndez-Menéndez Carlos Martínez-Campa SC. Complementary actions of melatonin on angiogenic factors, the angiopoietin/Tie2 axis and VEGF, in co-cultures of human endothelial and breast cancer cells. Oncol Rep 2017; 39(1): 433-41.
[40]
Miller SC, Pandi-Perumal SR, Pandi PSR, Esquifino AI, Cardinali DP, Maestroni GJM. The role of melatonin in immuno-enhancement: potential application in cancer. Int J Exp Pathol 2006; 87(2): 81-7.
[41]
Das R, Gregory PA, Fernandes RC, et al. MicroRNA-194 promotes prostate cancer metastasis by inhibiting SOCS2. Cancer Res 2017; 77(4): 1021-34.
[42]
Smolle MA, Leithner A, Posch F, Szkandera J, Liegl-Atzwanger B, Pichler M. MicroRNAs in different histologies of soft tissue sarcoma: a comprehensive review. Int J Mol Sci 2017; 18(9): 1960.
[43]
Qu S, Liu Z, Yang X, et al. The emerging functions and roles of circular RNAs in cancer. Cancer Lett 2018; 414: 301-9.
[44]
Kennedy L, Francis H, Meng F, Glaser S, Alpini G. Diagnostic and therapeutic potentials of microRNAs in cholangiopathies. Liver Res 2017; 1(1): 34-41.
[45]
Duggal B, Gupta MK, Naga PSV. Potential role of microRNAs in cardiovascular disease: are they up to their hype? Curr Cardiol Rev 2016; 12(4): 304-10.
[46]
Wang TH, Hsueh C, Chen CC, et al. Melatonin inhibits the progression of hepatocellular carcinoma through microRNA let7i-3p mediated RAF1 reduction. Int J Mol Sci 2018; 19(9): 2687.
[47]
Kim SJ, Kang HS, Lee JH, et al. Melatonin ameliorates ER stress-mediated hepatic steatosis through miR-23a in the liver. Biochem Biophys Res Commun 2015; 458(3): 462-9.
[48]
Mori F, Ferraiuolo M, Santoro R, et al. Multitargeting activity of miR-24 inhibits long-term melatonin anticancer effects. Oncotarget 2016; 7(15): 20532-48.
[49]
Zhu C, Huang Q, Zhu H. Melatonin inhibits the proliferation of gastric cancer cells through regulating the miR-16-5p-Smad3 pathway. DNA Cell Biol 2018; 37(3): 244-52.
[50]
Gu J, Lu Z, Ji C, et al. Melatonin inhibits proliferation and invasion via repression of miRNA-155 in glioma cells. Biomed Pharmacother 2017; 93: 969-75.
[51]
Marques JHM, Mota AL, Oliveira JG, et al. Melatonin restrains angiogenic factors in triple-negative breast cancer by targeting miR-152-3p: In vivo and in vitro studies. Life Sci 2018; 208: 131-8.
[52]
Mu J, Zhu D, Shen Z, et al. The repressive effect of miR-148a on Wnt/β-catenin signaling involved in Glabridin-induced anti-angiogenesis in human breast cancer cells. BMC Cancer 2017; 17(1): 307.
[53]
Li F, Liu W, Song Z, Chang D. miR-148a overexpression inhibits cell proliferation and induces cell apoptosis by suppressing the Wnt/β-catenin signal pathway in breast cancer MCF-7 cells. Int J Clin Exp Pathol 2016; 9(3): 3349-56.
[54]
Huang M-X. Down-expression of circulating micro ribonucleic acid (miRNA)-148/152 family in plasma samples of non-small cell lung cancer patients. J Cancer Res Ther 2016; 12(2): 671.
[55]
Zhao M, Su Z, Zhang S, Zhuang L, Xie Y, Li X. Suppressive role of microRNA-148a in cell proliferation and invasion in ovarian cancer through targeting transforming growth factor-b-induced 2. Oncol Res 2016; 24: 353-60.
[56]
Martínez-Campa C, González A, Mediavilla MD, et al. Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells. Br J Cancer 2009; 101(9): 1613-9.
[57]
Lee SE, Kim SJ, Youn J-P, Hwang SY, Park C-S, Park YS. MicroRNA and gene expression analysis of melatonin-exposed human breast cancer cell lines indicating involvement of the anticancer effect. J Pineal Res 2011; 51(3): 345-52.
[58]
Ge H, Shrestha A, Liu C, Wu P, Cheng B. MicroRNA 148a-3p promotes thrombospondin-4 expression and enhances angiogenesis during tendinopathy development by inhibiting Krüppel-like factor 6. Biochem Biophys Res Commun 2018; 502(2): 276-82.
[59]
Nooshinfar E, Safaroghli-Azar A, Bashash D, Akbari ME. Melatonin, an inhibitory agent in breast cancer. Breast Cancer 2017; 24(1): 42-51.
[60]
Mao L, Yuan L, Slakey LM, Jones FE, Burow ME, Hill SM. Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway. Breast Cancer Res 2010; 12(6): R107.
[61]
Jiang Q, He M, Ma M-T, et al. MicroRNA-148a inhibits breast cancer migration and invasion by directly targeting WNT-1. Oncol Rep 2016; 35(3): 1425-32.
[62]
Xue J, Chen Z, Gu X, Zhang Y, Zhang W. MicroRNA-148a inhibits migration of breast cancer cells by targeting MMP-13. Tumour Biol 2016; 37(2): 1581-90.

Rights & Permissions Print Cite
Article Metrics
68
5
© 2024 Bentham Science Publishers | Privacy Policy